The FDA approved atezolizumab (Tecentriq, Genentech) in combination with bevacizumab (Avastin, Genentech), paclitaxel and carboplatin for the first-line treatment of patients with metastatic nonsquamous, non-small cell lung cancer (NSCLC) with no EGFR or ALK tumor aberrations.
The approval was based on the multicenter, open-label, randomized controlled, phase 3 IMpower150 trial (ClinicalTrials.gov Identifier: NCT02366143) evaluating patients with stage IV or recurrent metastatic nonsquamous